Show simple item record

dc.contributor.advisorDing, Jiahuan.
dc.contributor.authorWood, David Rowe.
dc.contributor.otherBaylor University. Institute of Biomedical Studies.en
dc.date.accessioned2008-06-09T11:51:54Z
dc.date.available2008-06-09T11:51:54Z
dc.date.copyright2008-05
dc.date.issued2008-06-09T11:51:54Z
dc.identifier.urihttp://hdl.handle.net/2104/5153
dc.descriptionIncludes bibliographical references (p. 147-188).en
dc.description.abstractIt is the objective of this project to produce gene therapy vectors that are active and/or significantly up-regulated due to specific physiological conditions. The significance of such constructs is that it imparts a greater degree of control in the implementation of gene therapy. In general, it is desirable for a gene therapy vector to be active only when and where it is needed. The majority of gene therapy research to date has focused primarily on obtaining expression levels high enough to elicit a therapeutic response, as well as, distributing the vector to enough tissues to provide a corrective effect to the disorder being addressed. However, simply having a gene adequately delivered to enough cells to treat disease and having the gene product be produced in sufficient amounts to have a therapeutic effect cannot be the end of the story. Not unlike genes found naturally in the body, artificially delivered genes also need to be regulated. The construction of such vectors could prove useful for the treatment of disorders; such as Coronary Artery Disease (CAD) or even Cardiomyopathy, that occur in a specific tissue type or that are associated with an abnormal physiological state, such as hypoxia. Our vector constructs are a small step towards this ultimate goal. In this study, we present data on DNA vectors that were designed, constructed and evaluated in vitro and in vivo; both qualitatively and quantitatively. We report success in the creation of vectors/plasmids that are primarily cardiac tissue specific (pMHCI, pMHCII), vectors that are regulated by cellular oxygen levels (pHAL, pHAM), and even some success in combining the two (pHMHC).en
dc.description.statementofresponsibilityby David Rowe Wood.en
dc.format.extentxvii, 188 p. : ill.en
dc.format.extent805922 bytes
dc.format.extent85964 bytes
dc.format.extent5100819 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/pdf
dc.language.isoen_USen
dc.rightsBaylor University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. Contact librarywebmaster@baylor.edu for inquiries about permission.en
dc.subjectGenetic vectors.en
dc.subjectGenetic regulation.en
dc.subjectGene therapy.en
dc.titleDesign, optimization, and evaluation of conditionally active gene therapy vectors.en
dc.typeThesisen
dc.description.degreePh.D.en
dc.rights.accessrightsWorldwide accessen
dc.contributor.departmentBiomedical Studies.en


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record